{
    "title": "Pfizer's COVID product sales to top $50 bln this year, investors want more",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10489195/Pfizer-forecasts-54-bln-2022-sales-COVID-vaccine-pill.html",
    "date": "2022-02-08",
    "keywords": [
        "pfizer",
        "paxlovid",
        "vaccine",
        "price",
        "covid19",
        "year",
        "company",
        "erman",
        "pill",
        "street",
        "bourla",
        "treatment",
        "course",
        "version",
        "inc",
        "tuesday",
        "executive",
        "albert",
        "way",
        "outlook",
        "fraction",
        "conference",
        "call",
        "size",
        "order",
        "income",
        "line",
        "merck",
        "amp",
        "cos",
        "molnupiravir",
        "government",
        "capacity",
        "biontech",
        "drugmaker",
        "forecast",
        "decline",
        "world",
        "stock",
        "report",
        "dick",
        "trader",
        "trading",
        "llc",
        "malik",
        "business",
        "innovation",
        "officer",
        "cash",
        "infusion",
        "covid",
        "growth",
        "onset",
        "efficacy",
        "versus",
        "davinderpreet",
        "analyst",
        "pharma",
        "intelligence",
        "door",
        "drug",
        "reporting",
        "bengaluru",
        "michael",
        "jersey",
        "editing",
        "chakrabarty",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}